遗传性血管预防治疗:贝罗特拉斯塔特和兰德鲁马布的安全性概况
Mattia Donadoni1, Leyla La Cava1, Emanuele Bizzi2
1Internal Medicine, L. Sacco Hospital, ASST Fbf-Sacco, 20146 Milan, Italy.
Medicina (Kaunas, Lithuania)
|November 27, 2025
概括
这项研究比较了口服贝罗特拉斯塔特和皮下拉纳德鲁马布在遗传性血管 (HAE-C1-INH) 预防中的安全性. 贝罗特拉斯塔特显示胃肠道问题,而兰阿德鲁马布与注射部位反应和感染有关.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 遗传疾病 遗传性疾病
背景情况:
- 由于C1抑制剂缺乏 (HAE-C1-INH) 的遗传性血管需要长期预防 (LTP) 来管理反复发作的攻击.
- 卡利克林抑制剂是HAE-C1-INH的关键一线LTP疗法.
研究的目的:
- 为了比较口服贝罗特拉斯塔特和皮下拉纳德卢马布的安全性,这两种治疗HAE-C1-INH的第一线LTP疗法.
- 通过使用现实世界的数据,分析与这些疗法相关的不良药物反应 (ADR).
主要方法:
- 来自世卫组织VigiBase药监数据库的个体病例安全报告的回顾性定量分析.
- 在HAE-C1-INH患者中鉴定和比较贝罗特拉斯塔特和兰阿德鲁马布报告的副作用.
主要成果:
- 贝罗特拉斯塔特 (644份报告) 主要与胃肠道不良事件 (47.9%) 有关.
- 兰德鲁马布 (3432份报告) 显示,注射部位反应 (45.9%),感染 (23.3%),肌肉骨/连接组织疾病 (10%),免疫系统疾病 (5.3%),血管疾病 (4.7%) 和代谢问题 (3.9%) 的发病率较高.
- 在两组治疗中,女性患者更频繁地受到影响.
结论:
- 这些发现与有关贝罗特拉斯塔特的胃肠道副作用和兰阿德鲁马布注射部位反应和感染风险的现有文献一致.
- 与berotralstat相比,lanadelumab的使用与肌肉骨,免疫系统,血管和代谢障碍的频率更高有关.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
799
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
799
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
427
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
427
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895